HCLTECH
17.1.2024 10:31:27 CET | Business Wire | Press release
HCLTech, a leading global technology company, has emerged as the fastest-growing IT services brand with +15.9% YoY growth in brand value among the top 10 IT companies globally, as per the 2024 Brand Finance Global 500 and IT Services Top 25 Report released today in Davos.
Brand Finance, a leading independent brand valuation and strategy consultancy, adopted a methodology that evaluates a brand's strength based on its investments in marketing and brand initiatives, client and employee perception, and overall business performance. These findings come on the heels of HCLTech's strategic brand transformation efforts initiated 15 months ago. Led by a new brand identity and positioning, these efforts are anchored around Supercharging Progress™ and the company’s refreshed purpose - To bring together the best of technology and our people to supercharge progress.
Commenting on the update, Jill Kouri, Global CMO of HCLTech, said: "HCLTech’s business performance has surpassed the market across various key metrics. Our brand has been an important accelerator of this journey, helping reinforce our differentiation, further strengthen client and employee loyalty, showcase our abiding commitment to sustainability and CSR, and make it easier to connect with prospective clients in emerging markets. It is fulfilling to see our efforts recognized in the Brand Finance report.”
David Haigh, CEO of Brand Finance, highlighted: "We are highly impressed with the rapid and resilient increase in HCLTech's brand value and accelerated growth trajectory over the past few years. HCLTech stands out in terms of brand performance, excelling in both volume growth and the ability to drive profitability. This performance indicates a strong engagement with clients and an ability to capitalize on emerging market potential ahead of peer brands in the industry."
Over the last three decades, HCLTech has evolved as a leading global tech company offering a comprehensive portfolio encompassing digital, engineering, cloud, AI and software capabilities, which empowers clients in navigating end-to-end digital transformation. Fuelled by its holistic portfolio, core engineering DNA and decades of operational experience in AI, HCLTech stands at the pole position to unlock the best value from GenAI for its clients worldwide.
"The past year has been an exhilarating journey for our brand with a rejuvenated brand identity and positioning brought to life through best-in-class campaigns and platforms as well as through the actions, culture and values exhibited by our strong crew of over 224,000 HCLTechies who are our brand ambassadors. We are building on this momentum with strongly differentiated go-to-market campaigns this year,” said Zulfia Nafees, Global Head of Brand, HCLTech.
*Note for the Editors:
Top 10 IT Services providers as per Brand Finance Global 500 and IT Services Top 25 report are (in alphabetical order) -- Accenture, Capgemini, Cognizant, Fujitsu (IT Services), HCLTech, IBM Consulting, Infosys, NTT DATA, TCS, Wipro.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116270482/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
